IQVIA Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Cowen upgraded the rating on the stock to a Buy and gave it a $213.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Rhyee has given his Buy rating due to a combination of factors related to how artificial intelligence will affect IQVIA’s business and valuation. He now expects AI to trim overall outsourced clinical development costs by only about 10–15%, a far smaller impact than what the recent 20–40% sector share price decline seems to imply, and he believes pharma companies will recycle those savings into more trials and related work, helping to preserve revenue.
He also argues that IQVIA’s substantial AI investments should enable faster trial execution and support innovative, risk‑sharing contracts that can enhance margins and create a competitive edge. With the stock trading at roughly 14x his 2026 adjusted EPS estimate of $12.75 and reflecting overly pessimistic AI concerns, Rhyee sees an attractive risk‑reward setup, and he has modestly increased his long‑term RDS growth outlook to account for these dynamics.
In another report released on March 6, Barclays also upgraded the stock to a Buy with a $210.00 price target.